Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Keating

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
American Journal of Hematology|May 14, 2022
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysisHua-Jay J Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaWilliam Wierda, Susan O'Brien, Sijin Wen, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Blood|February 15, 2007
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Blood|October 16, 2004
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasStefan Faderl, Varsha Gandhi, Susan O'Brien, et al.
Cancer|December 4, 2018
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformationRashmi Kanagal-Shamanna, Preetesh Jain, Keyur P Patel, et al.
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
Blood|March 16, 2018
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Bruce D Cheson, Daniel Catovsky, et al.
Blood|October 17, 2015
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaSusan M O'Brien, Nicole Lamanna, Thomas J Kipps, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
American Journal of Hematology|May 14, 2022
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysisHua-Jay J Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaWilliam Wierda, Susan O'Brien, Sijin Wen, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Blood|February 15, 2007
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Blood|October 16, 2004
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasStefan Faderl, Varsha Gandhi, Susan O'Brien, et al.
Cancer|December 4, 2018
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformationRashmi Kanagal-Shamanna, Preetesh Jain, Keyur P Patel, et al.
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
Blood|March 16, 2018
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Bruce D Cheson, Daniel Catovsky, et al.
Blood|October 17, 2015
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaSusan M O'Brien, Nicole Lamanna, Thomas J Kipps, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Pageof 19